跳至主要内容
临床试验/EUCTR2016-001186-85-ES
EUCTR2016-001186-85-ES进行中(未招募)1 期

HIVEC HR: USE OF CHEMOHYPERTHERMIA WITH INTRAVESICAL MITOMYCIN (HIVEC) FOR THE TREATMENT OF PATIENTS WITH NMIBC AND HIGH RISK (HR) - HIVEC HR

Dr. Felipe Villacampa0 个研究点开始时间: 2016年6月1日最近更新:
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • 1. All patients operated of non invasive bladder tumour that meet high
  • risk criteria as per EORTC risk categories
  • 2. Above 18 years old
  • 3. Accept to participate in the trial and sign the consent form
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 25
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 25

排除标准

  • 1. Patients with invasive lesions or CIS
  • 2. Hypersensitivity or allergy to MMC
  • 3. History of severe adverse reaction to BCG
  • 4. Epithelial cells carcinoma involving prostatic urethra or upper urinary
  • 5. Patients with tumors histologically different than transitional cell
  • 6. Patients that for any reason should receive simultaneous
  • chemotherapy
  • 7. Withdrawal of CI
  • 8. Pregnant or lactating or women of childbearing age
  • who do not want or can not use non-hormonal contraceptives
  • 9. Urethral stenosis that contraindicates catheterization for the
  • instillation
  • 10. Treatment with immunosuppressants that contraindicates BCG

研究者

发起方
Dr. Felipe Villacampa

相似试验